Pulmonem Inc
Pulmonem Inc. was founded to demonstrate the effectiveness and safety of a reformulated and patented version of Dapsone, a generic drug, to arrest the development of inflammation caused by COVID-19 and help prevent hospitalization of those who become infected. Pulmonem has established manufacturing partnerships that will allow the Company to quickly bring this treatment to market soon after successful completion of clinical trials. Pulmonem is also pursuing solutions for the pediatric market, as well as alternative delivery systems, such as nasal sprays and liquids.
7-day free trial · no credit card
Verified contacts
2
available on Kipplo
LinkedIn employees
3
1 to 10 range
Open roles
—
no listings
Distinct roles
2
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 2 verified contacts at Pulmonem Inc
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
2 contacts with verified email or phone · masked until revealed.
Showing 1 of 2 verified contacts
Top roles at Pulmonem Inc
2 distinct titles indexed · top 2 shown.
- 1founder and ceo
- 1vice-président developpement commercial international
Sign up to unlock all 2 contacts at Pulmonem Inc
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 2 verified contacts at Pulmonem Inc
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.